DOCSLIB.ORG

Effect of Latanoprost Or 8-Iso Prostaglandin E2 Alone and in Combination on Intraocular Pressure in Glaucomatous Monkey Eyes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

LABORATORY SCIENCES Effect of Latanoprost or 8-iso Prostaglandin E2 Alone and in Combination on Intraocular Pressure in Glaucomatous Monkey Eyes Rong-Fang Wang, MD; Steven M. Podos, MD; Janet B. Serle, MD; Thomas W. Mittag, PhD; F. Ventosa, MD; Bernard Becker, MD Objective: To evaluate the possible additivity of the ef- duction of IOP of 4.0 ± 0.6 mm Hg was produced when fects of latanoprost and 8-iso prostaglandin E2 (8-iso PGE2) 8-iso PGE2 was added to latanoprost and of 3.0 ± 0.7 on intraocular pressure (IOP) in monkey eyes with laser- mm Hg was produced when latanoprost was added to 8-iso induced glaucoma. PGE2 on day 13 before the morning dosing. Combina- tion therapy with both agents caused maximum IOP re- Methods: The IOP was measured hourly for 6 hours be- ductions from baseline of 11.3 ± 3.0 mm Hg (33%) (P,.05) ginning at 9:30 AM on day 1 (baseline day), days 6 and 7 (latanoprost with 8-iso PGE2 added) and of 9.8 ± 1.3 , (single-agent therapy), and days 13 and 14 (combination mm Hg (31%) (P .01) (8-iso PGE2 with latanoprost added) therapy with both agents). Following 1 day of baseline mea- on day 14. surement, 4 monkeys with unilateral glaucoma received monotherapy twice daily with either 1 drop of 0.005% la- Conclusion: Latanoprost and 8-iso PGE2 have an addi- tanoprost, or 0.1% 8-iso PGE2, 25 µL, at 9:30 AM and 3:30 tive effect on IOP in glaucomatous monkey eyes. PM from days 2 through 7. From days 8 through 14, both agents were applied twice daily 5 minutes apart. Clinical Relevance: At least 50% of patients are treated with more than 1 ocular hypotensive medication. Thus, the Results: The maximum reduction of IOP (mean ± SEM) determinationoftheadditiveeffectsonIOPofglaucomamedi- was 8.8 ± 1.9 mm Hg (26%) (P,.05) with latanoprost alone cations will help to define optimum treatment regimens. , and 6.5 ± 1.0 mm Hg (21%) (P .01) with 8-iso PGE2 alone, 2 hours after the morning dosing on day 7. A further re- Arch Ophthalmol. 2000;118:74-77 ATANOPROST, a new prosta- appear to reduce IOP by 2 different mecha- glandin F2a analogue, has nisms have additive effects on IOP when been shown to be an effec- used in combination. tive ocular hypotensive agent 1,2 in patients with glaucoma RESULTS and in monkey eyes with laser-induced L3 glaucoma. The mechanism by which la- Latanoprost and 8-iso PGE2, when applied tanoprost reduces intraocular pressure as single agents, significantly (P,.05) re- From the Department of (IOP) is primarily by increasing uveo- duced the IOP for at least 18 hours after the Ophthalmology, Mount Sinai scleral outflow without notably affecting eighth dose, which was measured at the 0 School of Medicine of New York aqueous humor flow rates or tonographi- hour(trough)onstudyday6(Table).Maxi- University, New York cally measured outflow facility.4 mum reductions of IOP with single-agent (Drs Wang, Podos, Serle, and 8-iso Prostaglandin E (8-iso PGE ), Mittag); La Asociacion Para 2 2 therapy (peak) occurred 2 hours after the Evitar La Ceguera En Mexico, a novel bioactive prostaglandinlike com- morning dosing on day 7 and were 8.8 ± 1.9 IAP, Hospital Dr Luis Sanchez pound that is structurally different from la- mm Hg (26%) (P,.05) with latanoprost and Bulens, San Lucas Coyoacan, tanoprost, reduces IOP in normal and glau- 6.5 ± 1.0 mm Hg (21%) (P,.01) with 8-iso 5 Mexico, DF (Dr Ventosa); comatous monkey eyes. A substantial PGE2 (Table). Intraocular pressure reduc- and the Department of increase in outflow facility appears to ac- tions were similar comparing study day 6 Ophthalmology and Visual count for most of the IOP reduction in nor- withstudyday7oftreatmentwith8-isoPGE2 Science, Washington University mal monkey eyes.5 This implies that there (P..70)orcomparingstudyday6withstudy Medical School, St Louis, Mo are different mechanisms by which pros- day 7 of treatment with latanoprost (P..60). (Dr Becker). Dr Podos is a taglandins with different stereochemical or Intraocular pressure reductions were simi- consultant to Alcon Laboratories, Inc, Ft Worth, geometric configurations can affect aque- lar comparing study day 13 with study day Tex. Drs Podos, Mittag, and ous humor dynamics and lower IOP. 14 of treatment with latanoprost added to . Becker have a proprietary Thus, this study was designed to de- 8-iso PGE2 (P .40) or comparing study day interest in the drug evaluated in termine if 2 different prostaglandin de- 13 with study day 14 of treatment with 8-iso . this article. rivatives, latanoprost and 8-iso PGE2, that PGE2 added to latanoprost (P .80). The ARCH OPHTHALMOL / VOL 118, JAN 2000 WWW.ARCHOPHTHALMOL.COM 74 ©2000 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/24/2021 Effects of Single-Agent Therapy Followed by Combination Therapy on Intraocular Pressure MATERIALS AND METHODS in 4 Monkeys With Unilateral Glaucoma* Eight adult female cynomolgus monkeys (each weigh- Latanoprost + 8-iso Prostaglandin E2 + ing 3-5 kg), in which glaucoma had been induced uni- 8-iso Prostaglandin E2† Latanoprost‡ laterally by repeated argon or diode laser photoco- Trough (0 h) agulation of the midtrabecular meshwork, were used Baseline (day 1) 32.5 ± 1.9 33.3 ± 2.5 6 in this study. First drug The IOP was measured hourly, beginning at 9:30 Day 6 28.3 ± 1.3 (13)§ 29.5 ± 1.8 (11)§ AM, for a total of 6 hours on day 1 (baseline day), days Day 7 27.5 ± 1.9 (15)§ 29.0 ± 2.0 (13)§ 6and7(single-agenttherapy),anddays13and14(com- Both drugs bination therapy with both agents) using a calibrated Day 13 24.3 ± 1.3 (25)§\ 26.5 ± 2.1 (20)§\ pneumatonometer (model 30 classic; Mentor Inc, Nor- Day 14 24.0 ± 1.4 (26)§ 26.0 ± 1.6 (22)§\ well, Mass). Five minutes before tonometry, 1 drop of Peak (2 h) 0.5% proparacaine hydrochloride was topically applied, Baseline (day 1) 33.8 ± 3.5 31.5 ± 2.0 and ketamine hydrochloride, 1 to 5 mg/kg, was admin- First drug istered intramuscularly for adequate sedation. Day 6 25.5 ± 2.5 (24)§ 25.3 ± 1.5 (20)§ Day 7 25.0 ± 1.7 (26)§ 25.0 ± 1.7 (21)§ On each day of the study, 8-iso PGE2 (Cayman Chemical Co Inc, Ann Arbor, Mich) was freshly pre- Both drugs pared by dissolving in dimethyl sulfoxide, 100 g/L, and Day 13 22.0 ± 1.6 (35)§ 22.5 ± 1.3 (29)§ Day 14 22.5 ± 0.9 (33)§ 21.8 ± 1.0 (31)§\ diluting with 0.9% sodium chloride to a 0.1% solu- tion, a concentration that produces the greatest effect 5 *Data are given as the mean ± SEM (percentage reduction from baseline) on IOP. The commercially available preparation of la- intraocular pressure, measured in millimeters of mercury. Single-agent tanoprost, 0.005% (Pharmacia and Upjohn, Kalama- therapy and combination therapy were given twice daily. zoo, Mich), was used, which is also at the top of the †Treatment was started with 0.005% latanoprost, and 0.1% 8-iso dose-response relation. On the drug treatment days, prostaglandin E2 was added. days 2 through 14, the first IOP measurement was taken ‡Treatment was started with 0.1% 8-iso prostaglandin E2, and 0.005% latanoprost was added. just before the 9:30 AM dosing. On days 2 through 7, §Significant intraocular pressure reduction compared with baseline monkeys were treated twice daily with 1 drop of la- measurements (2-tailed paired t test, P,.05). tanoprost, or with 0.1% 8-iso PGE2, 25 µL, at 9:30 AM \Significant intraocular pressure reduction for combination therapy and 3:30 PM. On days 8 through 14, both 8-iso PGE2 compared with single-agent therapy (day 13 vs day 6 and day 14 vs day 7; and latanoprost were applied twice daily at 9:30 AM 2-tailed paired t test; P,.05). and 3:30 PM, 5 minutes apart. The monkeys were treated unilaterally, in the glaucomatous eye only. IOP reductions of up to 12% (3.8 ± 1.2 mm Hg) were noted The following statistical analyses were per- when 8-iso PGE was added to latanoprost and of up to 11% formed using the 2-tailed paired t test: the change in 2 IOP between baseline and single-agent therapy with (3.6 ± 0.8 mm Hg) were noted when latanoprost was added to 8-iso PGE 1 hour following morning dosing (Figure). latanoprost or 8-iso PGE2, the change in IOP be- 2 tween single-agent therapy and combination therapy, MaximumreductionsofIOPwithcombinationtherapycom- the change in IOP with single-agent therapy on days pared with baseline on day 14 were 11.3 ± 3.0 mm Hg (33%) , 6 and 7, the change in IOP with combination therapy (P .05) when 8-iso PGE2 was added to latanoprost and on days 13 and 14, and the change in IOP between 9.8 ± 1.3mmHg(31%)(P,.01)whenlatanoprostwasadded , combination therapy and baseline. A value of P .05 to 8-iso PGE2 (Table). was considered statistically significant. Data were cal- culated as the mean ± SEM. All experimental stud- ies complied with the Association for Research in Vi- COMMENT sion and Ophthalmology Resolution on the Use of Animals in Research and were approved by the Mount 8-iso Prostaglandin E2 is an isoprostane derivative. The iso- Sinai School of Medicine, New York, NY, Institu- prostanesareauniqueseriesofprostaglandinlikecompounds tional Animal Care and Utilization Committee.
Recommended publications
  • 202514Orig1s000

    202514Orig1s000

    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 202514Orig1s000 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) OFFICE OF CLINICAL PHARMACOLOGY REVIEW NDA: 202-514 Submission Date(s): January 7, 2011 Proposed Brand Name TBD Generic Name Tafluprost Primary Reviewer Yongheng Zhang, Ph.D. Team Leader Philip M. Colangelo, Pharm.D., Ph.D. OCP Division DCP4 OND Division DTOP Applicant MERCK & CO., Inc. Relevant IND(s) 062690 Submission Type; Code 1S(NME) Formulation; Strength(s) Tafluprost 0.0015% Ophthalmic Solution Indication For the reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension Dosage and Administration One drop of Tafluprost 0.0015% ophthalmic solution in the conjunctival sac of the affected eye(s) once daily in the evening TABLE OF CONTENTS 1. EXECUTIVE SUMMARY .................................................................................................................. 2 1.1. RECOMMENDATION ....................................................................................................................... 3 1.2. PHASE IV COMMITMENTS............................................................................................................. 3 1.3. SUMMARY OF IMPORTANT CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS FINDINGS.. 3 2. QUESTION BASED REVIEW ...........................................................................................................4 2.1. GENERAL ATTRIBUTES OF THE DRUG .........................................................................................
  • Blood-Aqueous Barrier Changes After the Use of Prostaglandin Analogues in Patients with Pseudophakia and Aphakia a 6-Month Randomized Trial

    Blood-Aqueous Barrier Changes After the Use of Prostaglandin Analogues in Patients with Pseudophakia and Aphakia a 6-Month Randomized Trial

    CLINICAL SCIENCES Blood-Aqueous Barrier Changes After the Use of Prostaglandin Analogues in Patients With Pseudophakia and Aphakia A 6-Month Randomized Trial Enyr S. Arcieri, MD; Alessandro Santana, MD; Fabiano N. Rocha, MD; Gustavo L. Guapo, MD; Vital P. Costa, MD Objectives: To investigate the effects of prostaglandin throughout follow-up (P Ͻ .02). Four latanoprost- analogues on the blood-aqueous barrier and to evaluate treated eyes, 1 bimatoprost-treated eye, and 1 travoprost- the occurrence of cystoid macular edema in aphakic or treated eye developed cystoid macular edema; all cases pseudophakic patients with glaucoma. resolved after discontinuation of the prostaglandin ana- logue and treatment with topical diclofenac sodium. Mean Methods: In this randomized, masked-observer, 6-month intraocular pressure reductions after 6 months were higher clinical trial, patients with primary open-angle, pseudo- for the latanoprost (26%), bimatoprost (28%), and tra- phakic, or aphakic glaucoma were treated once daily with voprost (29%) groups than for the control (3%) and uno- bimatoprost (n=16), latanoprost (n=15), or travoprost prostone (14%) groups (PϽ.05). Bimatoprost induced (n=17) or twice daily with unoprostone (n=16) or lu- significantly higher hyperemia scores than latanoprost, bricant drops (control group) (n=16). Blood-aqueous bar- unoprostone, and placebo (PϽ.01). rier status, which was assessed using a laser flare meter; intraocular pressure; the occurrence of angiographic cys- toid macular edema; and conjunctival hyperemia were Conclusion: Bimatoprost, latanoprost, and travoprost use evaluated. may lead to disruption of the blood-aqueous barrier in patients with pseudophakia and aphakia. Results: Mean flare values were significantly higher in the bimatoprost, latanoprost, and travoprost groups Arch Ophthalmol.
  • OBE022, an Oral and Selective Prostaglandin F2α Receptor Antagonist As an Effective and Safe Modality for the Treatment of Pret

    OBE022, an Oral and Selective Prostaglandin F2α Receptor Antagonist As an Effective and Safe Modality for the Treatment of Pret

    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/05/18/jpet.118.247668.DC1 1521-0103/366/2/349–364$35.00 https://doi.org/10.1124/jpet.118.247668 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:349–364, August 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics OBE022, an Oral and Selective Prostaglandin F2a Receptor Antagonist as an Effective and Safe Modality for the Treatment of Preterm Labor s Oliver Pohl, André Chollet, Sung Hye Kim, Lucia Riaposova, François Spézia, Frédéric Gervais, Philippe Guillaume, Philippe Lluel, Murielle Méen, Frédérique Lemaux, Vasso Terzidou, Phillip R. Bennett, and Jean-Pierre Gotteland ObsEva SA, Plan-les-Ouates, Geneva, Switzerland (O.P., A.C., J.-P.G.); Imperial College London, Parturition Research Group, Institute of Reproductive and Developmental Biology,HammersmithHospitalCampus,EastActon,London,UnitedKingdom(S.H.K.,L.R., V.T., P.R.B.); Citoxlab, Evreux, France (F.S., F.G.); Porsolt Research Laboratory, Le Genest-Saint-Isle, France (P.G.); Urosphere SAS, Toulouse, France (P.L., M.M.); BioTrial, Rennes, France (F.L.); and André Chollet Consulting, Tannay, Switzerland (A.C.) Downloaded from Received February 26, 2018; accepted May 15, 2018 ABSTRACT Preterm birth is the major challenge in obstetrics, affecting aggregation. In in vitro studies, OBE002 inhibited sponta- ∼ 10% of pregnancies. Pan-prostaglandin synthesis inhibitors neous, oxytocin- and PGF2a-induced human myometrial jpet.aspetjournals.org [nonsteroidal anti-inflammatory drugs (NSAIDs)] prevent preterm contractions alone and was more effective in combination labor and prolong pregnancy but raise concerns about fetal renal with atosiban or nifedipine.
  • Differential Activity and Clinical Utility of Latanoprost in Glaucoma and Ocular Hypertension

    Differential Activity and Clinical Utility of Latanoprost in Glaucoma and Ocular Hypertension

    Clinical Ophthalmology Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension Fernanda Pacella Background: The purpose of this study was to demonstrate the hypotensive efficacy and tolerability Paolo Turchetti of latanoprost when used as monotherapy and as polytherapy associated with antiglaucomatous Valentina Santamaria medication proven to be ineffective in keeping intraocular pressure under control. David Impallara Methods: Three hundred and thirty-seven patients (672 eyes) affected by primary open-angle Gianpaolo Smaldone glaucoma and intraocular hypertension were recruited over a period of 10 years from the Chiara Brillante Glaucoma Centre, Department of Ophthalmological Sciences, University of Rome “Sapienza”, and treated, subject to informed consent, with latanoprost 0.005% alone or in combination Aloisa Librando with other ocular hypotensive drugs. The patients were followed during this period at regular Angela Damiano intervals, with determination of visual field, fundus oculi, visual acuity, and eventual onset of Jose Pecori-Giraldi local and systemic side effects. Elena Pacella Results: Latanoprost used as monotherapy and as polytherapy renders possible optimal and Department of Sense Organs, durable control of intraocular pressure in the form of one antiglaucomatous drug because it can University of Rome “Sapienza”, substitute for one or more drugs and obtain the same hypotensive effect. Roma,
  • New York State Medicaid Drug Utilization Board Meeting Agenda

    New York State Medicaid Drug Utilization Board Meeting Agenda

    New York State Medicaid Drug Utilization Board Meeting Agenda The Drug Utilization (DUR) Board will meet April 24, 2014, from 9:00 a.m. to 4:30 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York Agenda Items Preferred Drug Program (PDP) The DUR Board will review therapeutic classes, described and listed below, as they pertain to the PDP. The therapeutic classes to be reviewed contain new relevant clinical and/or financial information. Therapeutic classes not included on this agenda may be reviewed at a later date. The Board will review new clinical and financial information as required, to recommend preferred and non-preferred drugs. ^ The Board will only consider clinical information which is new since the previous review of the therapeutic class and then consider financial information. New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials (comparative evidence is preferred, or placebo controlled when no head-to-head trials are available). Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of re-review and submission is discouraged. Those wishing to submit new clinical information must do so in an electronic format by April 9, 2014 or the Board may not have ample time to review the information. ^ The current preferred and non-preferred status of drugs subject to the Preferred Drug List (PDL) may be viewed at https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf
  • Success of Prostaglandin E2 in Structure–Function Is a Challenge for Structure-Based Therapeutics

    Success of Prostaglandin E2 in Structure–Function Is a Challenge for Structure-Based Therapeutics

    COMMENTARY Success of prostaglandin E2 in structure–function is a challenge for structure-based therapeutics Charles N. Serhan*† and Bruce Levy*‡ *Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine and ‡Critical Care and Pulmonary Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115 rostaglandin (PG) E2 is almost ubiquitous in humans and evokes potent diverse actions. Utility is the price of its perfec- Ption. PGE is a founding member of the 2 PGs, a class of mediators that belongs to the still growing family of bioactive au- tacoids known as the eicosanoids (1–3). The main classes include enzymatically generated products such as thrombox- anes, leukotrienes, lipoxins, and EETs, as well as others that are produced via nonenzymatic mechanisms, e.g., isopros- tanes and cyclopentaeone PGs that are increasing in number and appreciation (4, 5). PGE2 regulates key responses in the major human systems including re- productive, gastrointestinal, neuroendo- crine, and immune (Fig. 1). Formed by conversion of arachidonic acid via cyclo- oxygenase (COX) and specific synthases, Fig. 1. Diverse actions of PGE2 and selective targeted biosynthesis in inflammation. (Inset) Eicosanoid family major enzymatic classes of cyclooxygenases and lipoxygenase pathways (see text for details). PGE2 stereospecifically exerts potent (nano- to micromolar range) tissue- and cell type-selective actions (1–6). The importance of PGs in inflammation was from protecting gastrointestinal mucosa electrophoresis that this lipid-soluble brought into view by the discovery of J. to regulating smooth muscle and fever, activity behaved as an acid. Vane and colleagues (7) that nonsteroi- set a steep challenge for designer drug Bergstro¨m’s main research was in bile dal antiinflammatory drugs (NSAIDs) hunters to achieve, namely selectivity acids and steroids.
  • Effect of Prostanoids on Human Platelet Function: an Overview

    Effect of Prostanoids on Human Platelet Function: an Overview

    International Journal of Molecular Sciences Review Effect of Prostanoids on Human Platelet Function: An Overview Steffen Braune, Jan-Heiner Küpper and Friedrich Jung * Institute of Biotechnology, Molecular Cell Biology, Brandenburg University of Technology, 01968 Senftenberg, Germany; steff[email protected] (S.B.); [email protected] (J.-H.K.) * Correspondence: [email protected] Received: 23 October 2020; Accepted: 23 November 2020; Published: 27 November 2020 Abstract: Prostanoids are bioactive lipid mediators and take part in many physiological and pathophysiological processes in practically every organ, tissue and cell, including the vascular, renal, gastrointestinal and reproductive systems. In this review, we focus on their influence on platelets, which are key elements in thrombosis and hemostasis. The function of platelets is influenced by mediators in the blood and the vascular wall. Activated platelets aggregate and release bioactive substances, thereby activating further neighbored platelets, which finally can lead to the formation of thrombi. Prostanoids regulate the function of blood platelets by both activating or inhibiting and so are involved in hemostasis. Each prostanoid has a unique activity profile and, thus, a specific profile of action. This article reviews the effects of the following prostanoids: prostaglandin-D2 (PGD2), prostaglandin-E1, -E2 and E3 (PGE1, PGE2, PGE3), prostaglandin F2α (PGF2α), prostacyclin (PGI2) and thromboxane-A2 (TXA2) on platelet activation and aggregation via their respective receptors. Keywords: prostacyclin; thromboxane; prostaglandin; platelets 1. Introduction Hemostasis is a complex process that requires the interplay of multiple physiological pathways. Cellular and molecular mechanisms interact to stop bleedings of injured blood vessels or to seal denuded sub-endothelium with localized clot formation (Figure1).
  • Effects of Prostaglandin F2α (Pgf2α) on Cell-Death Pathways in the Bovine Corpus Luteum

    Effects of Prostaglandin F2α (Pgf2α) on Cell-Death Pathways in the Bovine Corpus Luteum

    Jonczyk et al. BMC Veterinary Research (2019) 15:416 https://doi.org/10.1186/s12917-019-2167-3 RESEARCH ARTICLE Open Access Effects of prostaglandin F2α (PGF2α) on cell- death pathways in the bovine corpus luteum (CL) Agnieszka Walentyna Jonczyk, Katarzyna Karolina Piotrowska-Tomala* and Dariusz Jan Skarzynski Abstract Background: Prostaglandin F2α (PGF2α) may differentially affect viability of luteal cells by inducing either proliferation or cell death (via apoptosis or necroptosis). The diverse effects of PGF2α may depend on its local vs. systemic actions. In our study, we determined changes in expression of genes related to: (i) apoptosis: caspase (CASP) 3, CASP8, BCL2 associated X (BAX), B-cell lymphoma 2 (BCL2) and (ii) necroptosis: receptor-interacting protein kinase (RIPK) 1, RIPK3, cylindromatosis (CYLD), and mixed lineage kinase domain-like (MLKL) in the early and mid-stage corpus luteum (CL) that accompany local (intra-CL) vs. systemic (i.m.) analogue of PGF2α (aPGF2α) actions. Cows at day 4 (n = 24) or day 10 (n = 24) of the estrous cycle were treated by injections as follows: (1) systemic saline, (2) systemic aPGF2α (25 mg; Dinoprost), (3) local saline, (4) local aPGF2α (2.5 mg; Dinoprost). After 4 h, CLs were collected by ovariectomy. Expression levels of mRNA and protein were investigated by RT-q PCR, Western blotting and immunohistochemistry, respectively. Results: We found that local and systemic administration of aPGF2α in the early-stage CL resulted in decreased expression of CASP3 (P < 0.01), but CASP8 mRNA expression was up-regulated (P < 0.05). However, the expression of CASP3 was up-regulated after local aPGF2α treatment in the middle-stage CL, whereas systemic aPGF2α administration increased both CASP3 and CASP8 expression (P < 0.01).
  • Efficacy and Safety of the Fixed Combinations of Tafluprost/Timolol

    Efficacy and Safety of the Fixed Combinations of Tafluprost/Timolol

    www.nature.com/scientificreports OPEN Efcacy and safety of the fxed combinations of tafuprost/timolol and latanoprost/carteolol Received: 4 February 2019 Masahiro Fuwa, Atsushi Shimazaki, Masafumi Mieda, Naoko Yamashita, Takahiro Akaishi, Accepted: 7 May 2019 Takazumi Taniguchi & Masatomo Kato Published: xx xx xxxx In this study, we made a comparative efcacy and safety assessment of two diferent fxed combinations of drugs, viz., tafuprost/timolol (TAF/TIM) and latanoprost/carteolol (LAT/CAR), by determining their efects on intraocular pressure (IOP) in ocular normotensive monkeys and examining their toxic efects on ocular surface using human corneal epithelial cells. TAF/TIM was found to be more efective in lowering IOP for a longer duration compared to LAT/CAR. We found that the diference in the intensity of IOP-lowering efect was because of the diferences in the strength of timolol compared with that of carteolol as a beta-adrenergic antagonist and strength of tafuprost compared with that of latanoprost as a prostaglandin analogue. In addition, TAF/TIM showed much less cytotoxic efects compared to LAT/CAR on the human corneal epithelial cells. Our fndings showed that TAF/TIM is better than LAT/CAR with regard to the IOP-lowering efect in monkeys and toxicity on ocular surface. Glaucoma is a neurodegenerative disease of the eyes characterised by selective retinal ganglion cell loss, fol- lowed by progressive defects in visual feld, resulting in the principal cause of irreversible blindness worldwide1–4. Elevated intraocular pressure (IOP) is an important contributor for the progression of glaucoma, for which the current treatment primarily involves IOP reduction1,5–8.
  • Unoprostone Isopropyl (Rescula) Reference Number: HIM.PA.11 Effective Date: 09.04.18 Last Review Date: 11.19 Revision Log Line of Business: HIM

    Unoprostone Isopropyl (Rescula) Reference Number: HIM.PA.11 Effective Date: 09.04.18 Last Review Date: 11.19 Revision Log Line of Business: HIM

    Clinical Policy: Unoprostone Isopropyl (Rescula) Reference Number: HIM.PA.11 Effective Date: 09.04.18 Last Review Date: 11.19 Revision Log Line of Business: HIM See Important Reminder at the end of this policy for important regulatory and legal information. Description Unoprostone isopropyl ophthalmic solution, 0.15% (Rescula®) is a synthetic analog (docosanoid) of prostaglandin F2-alpha. FDA Approved Indication(s) Rescula is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Rescula is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Ocular Hypertension or Open-Angle Glaucoma (must meet all): 1. Diagnosis of open-angle glaucoma or ocular hypertension; 2. Failure of prostaglandin analogues (e.g., latanoprost, travoprost, bimatoprost) in combination with beta blockers (e.g., timolol), unless contraindicated or clinically significant adverse effects are experienced; 3. Age ≥ 18 years; 4. Dose does not exceed 1 bottle per 35 days. Approval duration: 12 months B. Other diagnoses/indications 1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace. II. Continued Therapy A. Ocular Hypertension or Open-Angle Glaucoma (must meet all): 1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria; 2.
  • Prostaglandin Analogs for Glaucoma

    Prostaglandin Analogs for Glaucoma

    Prostaglandin Analogs Company Brand Generic Name Name Akorn Inc. Zioptan™ Tafluprost ophthalmic solution 0.0015% (PF) Allergan Inc. Durysta™ Bimatoprost 10 mcg implant Allergan Inc. Lumigan® Bimatoprost 0.01%, 0.03% Bausch & Lomb, Vyzulta™ Latanoprostene bunod 0.024% Inc. Novartis Travatan® Z Travaprost 0.004% Pfizer Inc. Xalatan® Latanoprost 0.005% Sun Ophthalmics Xelpros™ Latanoprost ophthalmic emulsion 0.005% Prostaglandin analogs work by increasing the outflow of intraocular fluid from the eye. They have few systemic side effects but are associated with changes to the eye itself, including change in iris color and growth of eyelashes. Depending on the individual, one brand of this type of medication may be more effective and produce fewer side effects. Prostaglandin analogs are taken as eye drops (except Durysta™ which is an implant). They are effective at reducing intraocular pressure in people who have open-angle glaucoma. Latanoprost and some formulations of bimatoprost and travoprost are available in generic form. Tafluprost is a preservative-free prostaglandin analog. Side Effects Side effects can include eye color change, darkening of eyelid skin, eyelash growth, droopy eyelids, sunken eyes, stinging, eye redness, and itching. Follow these steps to make it easier to put in eye drops: Preparing the Drops ● Always wash your hands before handling your eye drops or touching your eyes. ● If you’re wearing contact lenses, take them out — unless your ophthalmologist has ​ ​ told you to leave them in. ● Shake the drops vigorously before using them. ● Remove the cap of the eye drop medication. ○ Do not touch the dropper tip. Putting in Eye Drops ● Tilt your head back slightly and look up.
  • Appendix III

    Appendix III

    Appendix III NME LASA Names Azacitidine Cimetidine, famotidine, ranitidine, azathioprine, azulfidine, 1 (generic) capecitabine, zalcitabine Vidaza™ Videx, Vitrase, Viadur (brand) Cilostazol Sulfisoxazole, colestipol, clozaril, cozaar, inositol, aldactazide, 2 (generic) voriconazole Pletal™ Plendil (brand) Duloxetine Fluoxetine, atomoxetine, paroxetine, Dulcolax 3 (generic) Cymbalta™ Symbyax (brand) Erlotinib Gefitinib, imatinib 4 (generic) Tarceva™ Pexeva (brand) Eszopiclone Testolactone, buspirone, risperidone, ropinirole 5 (generic) Lunesta™ Menest, Cenestin, Lutera, Congestac, Nestabs (brand) Iloprost Bimatoprost, latanoprost, travoprost 6 (generic) Ventavis™ Ventolin inh., Ventuss Syrup, Tavist Syrup (brand) Orlistat Orlenta, Uristat 7 (generic) Xenical™ Xiral, Xeloda (brand) Pegaptanib Paganone, paraplatin, imatinib, gefitinib, Protonix 8 (generic) Macugen™ Adagen, magnesium sulfate, glucagen, mustargen, salagen (brand) Pemetrexed A-methapred, Penetrex, trimetrexate, ceftriaxone, Cetapred, Emetrol, 9 (generic) Medipred, Merrem, methotrexate Alimta™ Alinia, Elimite, Aceta, Adalimunab, Alfenta, Esclim (brand) Pramlintide Prandin 10 (generic) Symlin™ Insulin (brand) 11 Rifaximin Rifampin, rifapentine, rifabutin, Rifater Xifaxan™ Xanax, Biaxin Sibutramine Imipramine, topiramate 12 (generic) Meridia™ Mexitil, meperidine (brand) Telithromycin Erythromycin, clarithromycin, azithromycin, dirithromycin 13 (generic) Ketek™ Keflex, Keftab, K-pek, Kaopek (brand) Acamprosate Bacampicillin, acarbose, camptosar 14 (generic) Campral™ Camptosar, Keppra,